Home » Authors » Mark Lawson

Articles by Mark Lawson

AusBiotech, ASX Working To Finalize Reporting Guidelines

Nov. 10, 2004

AusBiotech, ASX Working To Finalize Reporting Guidelines

Nov. 10, 2004

Narhex Seeks A$8M IPO To Develop HIV Drug In China

Nov. 3, 2004

Narhex Seeks A$8M IPO To Develop HIV Drug In China

Nov. 3, 2004

Allergan Returns Rights To PEP005; Peplin's Stock Falls

Oct. 20, 2004

Allergan Returns Rights To PEP005; Peplin's Stock Falls

Oct. 20, 2004

Biota, Consortium Bring In $10M In NIAID Grant Money

Oct. 6, 2004

Metabolic Pays For Research Note; Stock Price Rises, Falls

July 14, 2004

Metabolic Pays For Research Note; Stock Price Rises, Falls

July 14, 2004

No Remicade Valuation Spoils Peptech, Agenix A$500 Merger

June 23, 2004

SYDNEY, Australia - A friendly A$500 million (US$345 million) merger that promised to create Australia's largest pure biotech company has been called off after hitting a major obstacle over one partner's dispute with a U.S. company. (BioWorld International)